Kyowa Kirin International News and Activities

Kyowa Kirin International is owned by Kirin.

Kirin is one of the...

• Forbes Global 2000 (#1280);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Kirin is a company listed under the stock ticker 2503 (JP).

Kirin has a direct presence in 3 countries.

Kirin has 6 subsidiaries including Coca-Cola Beverages Northeast, Kyowa Chemical Industry and Kyowa Hakko Kirin.

They are in:

• Beverages29%
• Pharmaceuticals29%
• Other43%

View the org chart displaying its 25 main executives

Most searched biographies at Kyowa Kirin International

• Julie Dehaene Puype, President
• Paula Soteropoulos, Director
• Wayne Bowler, Senior Vice President, Business Development & Allian...

Popular executive movements at Kyowa Kirin International

• Richard Johnson, Senior Vice President of Head of Strategy and Human Resources, has left the company  (posted on May 5 2026).

Create your alert
to follow the executive moves at Kyowa Kirin International.

Kirin has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Corden Pharma has announced the acquisition of AmbioPharm  (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by Kyowa Kirin International

• Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML - Kyowa Kirin
• Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials - Kyowa Kirin
• Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis - Kyowa Kirin
• Kyowa Kirin Highlights Positive Phase 3 Topline Data from BridgeBio’s Global PROPEL 3 Study of Infigratinib in Achondroplasia - Kyowa Kirin
• Kyowa Kirin Announces Changes in Directors and Management Structure - Kyowa Kirin
• Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel | Orchard Therapeutics
• Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025 | Orchard Therapeutics
• Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
• Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day | Orchard Therapeutics
• CTCL Global Care Collaborative Pioneers Consensus for Improving Diagnosis and Care in Cutaneous T-Cell Lymphoma (CTCL)
• View more press releases Close

Social media about Kyowa Kirin International

• Kyowa Kirin International on Wikipedia, Google News & Yahoo Finance
• Kyowa Kirin International on LinkedIn, X (Twitter) & YouTube